Cell Genesys, Inc. (CEGE)

Babsly (23.67) Submitted: 12/03/07 4:41 PM : Start Price: $2.26 CEGE Score: 53.86

Cell Genisis is due to report information on their outstanding GVAX prostate cancer vaccine trials that are in stage III and II. The results are pitched as being positive by the knowledgeable few, and if you don't get in before the hype, you've missed the boat. Its lag time is over, the smart biotech investor knows the stock is more likely to down trend while trials of a possible blockbuster drug are in process. When results are due and the concensus points to positive info, especially drugs in early phase III stages, the stock will bounce with volume. The MACD along with other indicators( even though this is not a gtraditional co.) all point to the stock price at the beginning of a big upward move. If there is even a glitter of hope these type of stocks bounce big, here it comes.

Report this Post Replies: 0 | Reply